Real-time PCR (qPCR) Assay Market

Report Overview

The global real-time PCR (qPCR) assay market was pegged at US$ 4.10 in 2021 and is expected to witness a CAGR of 7.4% during the forecast period.

Market Fundamentals

Polymerase chain reaction (PCR) utilizes polymerase enzymes, primers, and multiple thermal cycles to generate an infinite number of copies of DNA from a single strand. Because PCR diagnostics are performed in automated thermal cyclers, they are less susceptible to cross-contamination. Real-time PCR (qPCR) is a common diagnostic technique used in research in pharmaceutical and biotech institutes, and it is extensively used in a wide range of life sciences applications.

Real-time PCR enables specific and early disease diagnosis, allowing patients to receive the appropriate response and targeted treatment at a quick turnaround time. Additionally, PCR techniques are more specific than traditional infectious disease detection methods such as immunoassays and have become an integral part of diagnostic laboratories, facilitating market growth.

[898765]

Market Dynamic

An increase in the incidence of infectious diseases and genetic disorders, as well as growth in the number of diagnostic centres and hospitals, are the prime reasons to drive the real-time PCR (qPCR) assay market. Over the last decade, there has been a significant increase in the use of genomic analysis tools in the diagnosis of major infectious diseases (such as HIV, tuberculosis, malaria, and hepatitis) and genetic abnormalities (such as cancer). The increasing global prevalence of targeted disease, combined with the demonstrated efficacy of qPCR analysis in the diagnosis and estimation of disease-causing microorganisms, will drive clinical diagnostic test adoption and qPCR market expansion. However, high costs associated with the instruments and the need for capital investment on a larger scale to develop advanced devices are pulling forces for the market growth. 

Market Ecosystem

The global real-time PCR (qPCR) assay market has been segmented by Product, Application, End User, and Region.

Real-time PCR (qPCR) Assay Market by Product Type

[5746534343]

Based on product type, the global real-time PCR (qPCR) assay market has been segmented into reagents & consumables, and instruments. The reagents & consumables segment dominated the market during the forecast period due to the emergence of the COVID-19 pandemic, increased demand for early disease detection, and a multitude of significant companies producing qPCR consumables and reagents. Furthermore, the widespread use of consumables and reagents, as well as the growing demand for healthcare, research, and other purposes, contribute to the segment's large share. Moreover, the rising prevalence of chronic diseases, as well as increased use of qPCR, has increased the demand for consumables and reagents. Besides this, the pharmaceutical and healthcare industries' increasing acceptance of technological innovations, as well as increased R&D, will generate a significant potential for this market over the forecast period.

Template cDNA, upstream and downstream primers, GoTaq DNA polymerase with reaction buffer, dNTP mixture, molecular grade, nuclease-free water, and agarose are the various reagents and assays used for real-time PCR. Furthermore, real-time PCR consumables include plastics and supplies for qPCR experiments, including tubes, plates, caps, adhesive plate seals, strips, and racks. They are supported for optimal performance with real-time PCR systems. 

Real-time PCR (qPCR) Assay Market by Application

Based on application, the global real-time PCR (qPCR) assay market has been segmented into clinical research and forensics. The clinical segment held the largest revenue share during the forecast period. This can be attributed to a variety of factors, including the rising prevalence of diseases such as cancer, infectious diseases, and diabetes, high precision of testing methods, increased commercialization of diagnostic reagents, efficient disease diagnosis, monitoring, and treatment, and additional benefits in disease detection. However, the forensic segment is likely to register the fastest growth during the forecast period. The segment is expected to be driven by the increasing use of novel techniques in forensic applications such as DNA typing, genetic fingerprinting, and DNA testing.

Real-time PCR (qPCR) Assay Market by End User

Based on end user, the global real-time PCR (qPCR) assay market has been segmented into hospitals & diagnostic centres, academic & research institutes, pharmaceutical & biotechnology industries, and others. The hospitals and diagnostic centres segment reported the largest share of the market during the forecast period. This can be attributed to the growing demand for early and efficient disease diagnosis and treatment, the increasing number of qPCR product launches for diagnostic applications, the advantages of qPCR in disease diagnosis (when compared to other PCR technologies) and growing public awareness of the advantages of qPCR in disease diagnosis.

Real-time PCR (qPCR) Assay Market by Region

Based on the region, the global real-time PCR (qPCR) assay market has been segmented into North America, Europe, Asia Pacific, and the Rest of the World (RoW). North America attributed the highest growth during the forecast period. The increasing adoption of advanced and original genomic analysis products, including innovative Real-time PCR (qPCR) products, is primarily responsible for the growth of the North American real-time PCR (qPCR) assay market. The increased availability of R&D funding for genomic research, combined with the region's robust research infrastructure, is driving the growth of the real-time PCR (qPCR) assay market in North America. When compared to other regions, North America is witnessing rapid growth due to the early commercialization of several real-time PCR (qPCR) products, giving the region an early bird advantage.

Competitive Landscape

Some renowned players operating in the global real-time PCR (qPCR) assay market are 

• Thermo Fisher Scientific Inc
• Bio-Rad Laboratories Inc
• Abbott Laboratories inc
• F. Hoffmann-La Roche, Ltd
• Becton Dickinson and Company
• Analytik Jena AG
• Agilent Technologies Inc
• Eppendorf AG
• Fluidigm Corporation
• Merck KGaA
• Takara Bio
• Qiagen N.V. 

Strategic Developments

• In December 2021, Bio-Rad used its cash position to acquire Dropworks for approximately $ 125 million. Dropworks is developing a droplet-based digital PCR system that could provide a more cost-effective solution for improving PCR workflow and assisting Bio-Rad in entering the lower-end segment for their ddPCR platforms. Bio-Rad can continue to make similar deals and ensure future growth by utilizing its cash position.
• In March 2020, Abbott Laboratories launched the m2000 RealTime SARS-CoV-2 EUA test, which also runs on the m2000 RealTime System, found in hospitals and reference labs around the world. The company intends to produce approximately 5 million tests per month.
• In April 2019, Thermo Fisher Scientific Inc. announced the QuantStudio 6 and 7 Pro Real-Time PCR Systems, which include new features such as facial authentication, voice command, and radiofrequency identification.

Frequently Asked Questions About This Report